These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 20224643)
21. The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics. Angelova A; Rommelaere J; Ungerechts G Pathogens; 2024 Feb; 13(3):. PubMed ID: 38535528 [TBL] [Abstract][Full Text] [Related]
23. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558 [TBL] [Abstract][Full Text] [Related]
24. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661 [TBL] [Abstract][Full Text] [Related]
25. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703 [TBL] [Abstract][Full Text] [Related]
26. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies. Shah S Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077 [TBL] [Abstract][Full Text] [Related]
33. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Chuntova P; Chow F; Watchmaker PB; Galvez M; Heimberger AB; Newell EW; Diaz A; DePinho RA; Li MO; Wherry EJ; Mitchell D; Terabe M; Wainwright DA; Berzofsky JA; Herold-Mende C; Heath JR; Lim M; Margolin KA; Chiocca EA; Kasahara N; Ellingson BM; Brown CE; Chen Y; Fecci PE; Reardon DA; Dunn GP; Liau LM; Costello JF; Wick W; Cloughesy T; Timmer WC; Wen PY; Prins RM; Platten M; Okada H Neuro Oncol; 2021 Mar; 23(3):356-375. PubMed ID: 33367885 [TBL] [Abstract][Full Text] [Related]
34. Oncolytic Virotherapy in Glioma Tumors. Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689 [TBL] [Abstract][Full Text] [Related]
35. Cancer Treatment Goes Viral: Using Viral Proteins to Induce Tumour-Specific Cell Death. Wyatt J; Müller MM; Tavassoli M Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817939 [TBL] [Abstract][Full Text] [Related]
36. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. Bretscher C; Marchini A Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641 [TBL] [Abstract][Full Text] [Related]
37. Virus-Based Immunotherapy of Glioblastoma. Martikainen M; Essand M Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30764570 [TBL] [Abstract][Full Text] [Related]
38. The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers. Angelova AL; Witzens-Harig M; Galabov AS; Rommelaere J Front Oncol; 2017; 7():93. PubMed ID: 28553616 [TBL] [Abstract][Full Text] [Related]